Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results